<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02108743</url>
  </required_header>
  <id_info>
    <org_study_id>IRB8603</org_study_id>
    <nct_id>NCT02108743</nct_id>
  </id_info>
  <brief_title>Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension</brief_title>
  <official_title>Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American Medical Association Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>American Medical Association Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if dynamic hyperinflation seen in patients with
      idiopathic pulmonary artery hypertension (iPAH) improves with albuterol therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Only a few small studies have evaluated the relationship between iPAH, expiratory flow
      limitation, and exercise dyspnea. While not all patients with iPAH demonstrate airway
      involvement, those who demonstrate dynamic hyperinflation (DH), defined as a variable and
      temporary increase in end-expiratory lung volume, report increased dyspnea with exertion on
      maximal testing. There is a continued need for adjuvant therapy in iPAH, and bronchodilators
      have the potential to ameliorate dyspnea during exercise, which could lead to improved
      quality of life in this disabling condition. This study will investigate the presence of
      airway involvement in this population as measured by dynamic hyperinflation, and if there is
      any improvement in function with the use of inhaled albuterol.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lack of funding
  </why_stopped>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>End-expiratory lung volume:total lung capacity (EELV/TLC) ratio at matched metabolic isowork.</measure>
    <time_frame>up to 3 days</time_frame>
    <description>Determined by measuring inspiratory capacity every 2 minutes during cardiopulmonary exercise test (CPET)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in peak oxygen consumption with albuterol</measure>
    <time_frame>Study days 2 and 3</time_frame>
    <description>Measured at the end of CPET</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in O2 pulse with albuterol.</measure>
    <time_frame>Study days 2 and 3</time_frame>
    <description>Measured throughout CPET and compared at matched metabolic isotimes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise time</measure>
    <time_frame>Study days 2 and 3</time_frame>
    <description>Total ramped exercise time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Borg dyspnea score</measure>
    <time_frame>Days 2 and 3</time_frame>
    <description>Measured every 2 minutes throughout CPET</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Idiopathic Pulmonary Arterial Hypertension.</condition>
  <arm_group>
    <arm_group_label>Albuterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.5 mg of albuterol inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline placebo inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albuterol.</intervention_name>
    <description>2.5 mg of albuterol inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.</description>
    <arm_group_label>Albuterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline placebo</intervention_name>
    <description>Placebo inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or greater.

          -  Idiopathic Pulmonary Arterial Hypertension, or Familial Pulmonary Arterial
             Hypertension.

          -  Forced expiratory flow 75% (FEF75%) of ≤ 65% of predicted.

        Exclusion Criteria:

          -  Clinical instability or change in medication therapy in preceding 3 months.

          -  Allergy or intolerance to inhaled albuterol.

          -  Body mass index &gt; 30

          -  Active tobacco use, or &gt; 10 pack-year smoking history.

          -  Lung disease other than pulmonary hypertension

          -  Forced expiratory volume in 1 second (FEV1) ≤ 80% of predicted.

          -  Pregnancy

          -  Inability to perform pulmonary function testing.

          -  Inability to perform cardiopulmonary exercise testing.

          -  Supplemental oxygen requirement.

          -  Inability to read and understand English.

          -  Historical 6-minute walk distance &lt;150 meters
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Lammi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Louisiana State University Health Sciences Center in New Orleans</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LSUHSC Interim Louisiana Hospital</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Meyer FJ, Ewert R, Hoeper MM, Olschewski H, Behr J, Winkler J, Wilkens H, Breuer C, Kübler W, Borst MM; German PPH Study Group. Peripheral airway obstruction in primary pulmonary hypertension. Thorax. 2002 Jun;57(6):473-6.</citation>
    <PMID>12037220</PMID>
  </reference>
  <reference>
    <citation>Fernandez-Bonetti P, Lupi-Herrera E, Martinez-Guerra ML, Barrios R, Seoane M, Sandoval J. Peripheral airways obstruction in idiopathic pulmonary artery hypertension (primary). Chest. 1983 May;83(5):732-8.</citation>
    <PMID>6839814</PMID>
  </reference>
  <reference>
    <citation>Laveneziana P, Garcia G, Joureau B, Nicolas-Jilwan F, Brahimi T, Laviolette L, Sitbon O, Simonneau G, Humbert M, Similowski T. Dynamic respiratory mechanics and exertional dyspnoea in pulmonary arterial hypertension. Eur Respir J. 2013 Mar;41(3):578-87. doi: 10.1183/09031936.00223611. Epub 2012 Jul 12.</citation>
    <PMID>22790921</PMID>
  </reference>
  <reference>
    <citation>Spiekerkoetter E, Fabel H, Hoeper MM. Effects of inhaled salbutamol in primary pulmonary hypertension. Eur Respir J. 2002 Sep;20(3):524-8.</citation>
    <PMID>12358324</PMID>
  </reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2014</study_first_submitted>
  <study_first_submitted_qc>April 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2014</study_first_posted>
  <last_update_submitted>December 29, 2015</last_update_submitted>
  <last_update_submitted_qc>December 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Louisiana State University Health Sciences Center in New Orleans</investigator_affiliation>
    <investigator_full_name>Matthew Lammi</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine, Section of Pulmonary and Critical Care</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

